

15 - References

References

Prescribing in children and adolescents CHAPTER 5 References

1. Pina-Camacho L, et al. Autism spectrum disorder and schizophrenia: boundaries and uncertainties. *BJPsych Advances* 2016; 22:316–324.
2. Hayes D, et al. Dilemmas in the treatment of early-onset first-episode psychosis. *Ther Adv Psychopharmacol* 2018; 8:231–239.
3. Kumra S, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. *Schizophr Bull* 2008; 34:60–71.
4. Singappuli P, et al. Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. *CNS Spectr* 2022; 27:570–587.
5. Lee ES, et al. Psychopharmacologic treatment of schizophrenia in adolescents and children. *Child Adolesc Psychiatr Clin N Am* 2020; 29:183–210.
6. Connor DF, et al. Neuroleptic-related dyskinesias in children and adolescents. *J Clin Psychiatry* 2001; 62:967–974.
7. Campbell M, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. *J Am Acad Child Adolesc Psychiatry* 1997; 36:835–843.
8. Sikich L, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. *Neuropsychopharmacology* 2004; 29:133–145.
9. Sikich L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. *Am J Psychiatry* 2008; 165:1420–1431.
10. Kryzhanovskaya L, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2009; 48:60–70.
11. Haas M, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. *J Child Adolesc Psychopharmacol* 2009; 19:611–621.
12. Haas M, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. *Br J Psychiatry* 2009; 194:158–164.
13. Findling RL, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. *Am J Psychiatry* 2008; 165:1432–1441.

14. Pagsberg AK, et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. *Lancet Psychiatry* 2017; 4:605–618.
15. Findling RL, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo- controlled trial. *J Child Adolesc Psychopharmacol* 2012; 22:327–342.
16. Singh J, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. *Biol Psychiatry* 2011; 70:1179–1187.
17. Arango C, et al. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. *Eur Child Adolesc Psychiatry* 2019; 29:1195–1205.
18. Pagsberg AK, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. *J Am Acad Child Adolesc Psychiatry* 2017; 56:191–202.
19. Lopez-Morinigo JD, et al. Pharmacological treatment of early-onset schizophrenia: a critical review, evidence-based clinical guidance and unmet needs. *Pharmacopsychiatry* 2022; 55:233–245.
20. Jensen KG, et al. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. *Psychopharmacology (Berl)* 2018; 235:681–693.
21. Goldman R, et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6--week, randomized placebo-controlled study. *J Child Adolesc Psychopharmacol* 2017; 27:-516–525.
22. Baeza I, et al. What role for long-acting injectable antipsychotics in managing schizophrenia spectrum disorders in children and adolescents? A systematic review. *Paediatr Drugs* 2023; 25:135–149.
23. Sunshine A, et al. Practitioner review: psychosis in children and adolescents. *J Child Psychol Psychiatry* 2023; 64:980–988.
24. Correll CU, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. *World Psychiatry* 2020; 19:69–80.
25. Kumra S, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. *Arch Gen Psychiatry* 1996; 53:1090–1097.
26. Shaw P, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine--olanzapine comparison. *Arch Gen Psychiatry* 2006; 63:721–730.
27. Kumra S, et al. Clozapine and 'high-dose' olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. *Biol Psychiatry* 2008; 63:524–529.
28. Schneider C, et al. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. *Eur Psychiatry* 2014; 29:1–10.
29. Adnan M, et al. Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. *J Child Adolesc Psychopharmacol* 2022; 32:2–11.
30. Agid O, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. *J Clin Psychiatry* 2011; 72:1439–1444.

31. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Clinical Guidance [CG155]. 2013 (last updated October 2016, last checked October 2023); <https://www.nice.org.uk/guidance/cg155>.
 32. Catalan A, et al. Annual research review: prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention. *J Child Psychol Psychiatry* 2021; 62:657–673.
 33. Lång U, et al. Systematic review and meta-analysis: psychosis risk in children and adolescents with an at-risk mental state. *J Am Acad Child Adolesc Psychiatry* 2022; 61:-615–625.
-

Revision #1

Created 2026-01-04 20:16:34 UTC by Omar Ayman

Updated 2026-01-04 20:16:34 UTC by Omar Ayman